insights_auto
Why is GILD up 2,49%?
Dive Deeperchevron_right
GILD:NASDAQ
Gilead Sciences, Inc
USD 157,37
arrow_upward
+2,49%(+3,83) 1D
USD 157,68
arrow_upward
+0,20% (+0,31)bedtimeAfter hours
Closed: 15 Okt., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GILD...
Open
USD 156,39
High
USD 160,51
Low
USD 156,02
Mkt. cap
195,13 mjd
Avg. vol.
5,67 m
Volume
8,29 m
Dividend
2,08%
Quarterly dividend
USD 0,82
Ex-dividend date
15 Sep. 2026
52-wk high
USD 160,51
52-wk low
USD 114,02
EPS
-USD 2,66
Beta
0,32
Shares outstanding
1,24 mjd
No. of employees
17 k
Open
USD 156,39
High
USD 160,51
Low
USD 156,02
Mkt. cap
195,13 mjd
Avg. vol.
5,67 m
Volume
8,29 m
Dividend
2,08%
Quarterly dividend
USD 0,82
Ex-dividend date
15 Sep. 2026
52-wk high
USD 160,51
52-wk low
USD 114,02
EPS
-USD 2,66
Beta
0,32
Shares outstanding
1,24 mjd
No. of employees
17 k
News stories
From web sources and news partners
scanx.trade
·
2 minute gelede
Gilead Sciences Q3FY26 Results: Earnings release set for October 29, 2026
Zacks
·
1 uur gelede
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Yahoo Finance UK
·
2 uur gelede
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
News Corp
·
2 uur gelede
Gilead and Cardinal Health Stocks Jump to Record Highs. Why Healthcare Is on a Tear.
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17 k
Founded22 Jun. 1987
HeadquartersFoster City, Kalifornië, Verenigde State van Amerika
Sector-
Websitegilead.com